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ABSTRACT 
The von Hippel-Lindau (VHL) tumor suppressor gene is inactivated in the majority of clear cell 
renal cell carcinomas (ccRCC), but genetic ablation of Vhl alone in mouse models is insufficient to 
recapitulate human tumorigenesis. One function of pVHL is to regulate the stability of the hypoxia-
inducible factors (HIF), which become constitutively activated in the absence of pVHL. In 
established ccRCC, HIF-1α has been implicated as a renal tumor suppressor, whereas HIF-2α is 
considered an oncoprotein. In this study, we investigated the contributions of HIF-1α and HIF-2α 
to ccRCC initiation in the context of Vhl deficiency. We found that deleting Vhl plus Hif1a or Hif2a 
specifically in the renal epithelium did not induce tumor formation. However, HIF-1α and HIF-2α 
differentially regulated cell proliferation, mitochondrial abundance and oxidative capacity, 
glycogen accumulation, and acquisition of a clear cell phenotype in Vhl-deficient renal epithelial 
cells. HIF-1α, but not HIF-2α, induced Warburg-like metabolism characterized by increased 
glycolysis, decreased oxygen consumption, and decreased ATP production in mouse embryonic 
fibroblasts, providing insights into the cellular changes potentially occurring in Vhl mutant renal 
cells before ccRCC formation. Importantly, deletion of either Hif1a or Hif2a completely prevented 
the formation of renal cysts and tumors in Vhl/Tp53 mutant mice. These findings argue that both 
HIF-1α and HIF-2α exert pro-tumorigenic functions during the earliest stages of cyst and tumor 
formation in the kidney. 
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INTRODUCTION 
Clear cell renal cell carcinoma (ccRCC) is the most frequent renal malignancy and up to 92% of 
ccRCC tumors harbor biallelic inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene 
(1). VHL mutations occur at the earliest stage of tumor formation (2). The absence of pVHL 
function is clearly necessary for the growth of fully transformed ccRCC cell lines as xenografts (3). 
However, the fact that the frequency of VHL mutant single epithelial cells vastly outweighs the 
number of ccRCC tumors in kidneys of familial VHL disease patients (4) and the absence of tumors 
in a variety of renal epithelial cell-specific Vhl knockout mice (reviewed in (5)) argues that ccRCC 
formation requires mutations in addition to VHL. There are currently no autochthonous mouse 
models that fully reproduce all of the characteristic morphological and invasive properties of human 
ccRCC, however, consistent with the hypothesis that multiple cooperating mutations are required 
for ccRCC development, kidney epithelial cell-specific co-deletion of Vhl with Pten (6), or with 
Kif3a to genetically ablate primary cilia (7), caused the formation of simple and atypical cystic 
lesions that are similar to the ccRCC precursor cystic lesions found in the kidneys of patients with 
inherited VHL disease. Deletion of Vhl together with homozygous loss of Trp53 (8) or with 
heterozygous loss of Bap1 (9), gave rise to very similar phenotypes, including simple and atypical 
cystic lesions as well as tumors containing cells that display cytoplasmic clearing and elevated 
mTORC1 activity, recapitulating many of the cellular and molecular changes that are characteristic 
of human ccRCC. 
 
pVHL controls many biological activities including regulation of the stability of the hypoxia-
inducible transcription factors α (HIF-1α, HIF-2α and HIF-3α, collectively HIF-α) (10), regulation 
of NF-κB activity (11), maintenance of the primary cilium (12), activation of p53 (13), secretion of 
extracellular matrix components (14), promotion of DNA double strand repair (15), regulation of 
the plane of cellular division (16,17) and suppression of aneuploidy (16,18). The combined loss of 
several or all of pVHL’s functions could contribute to tumor initiation and progression. Loss of 
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function mutations of VHL occur in ccRCC mutually exclusively to rarer mutations in TCEB1, 
encoding Elongin C, and collectively these cause constitutive stabilization of HIF-α in up to 95% of 
ccRCC tumors (1), implying that HIF-α activation is a major oncogenic driving force in ccRCC. 
HIF-1α and HIF-2α appear to play opposite roles in determining the aggressiveness of established 
ccRCCs; HIF-1α inhibits, whereas HIF-2α promotes tumor formation in ccRCC xenografts (19-
21), copy loss of the chromosomal locus harboring the HIF1A gene predicts poor patient outcome 
(22) and sporadic ccRCCs expressing HIF-1α and HIF-2α exhibit lower proliferation rates than 
ccRCCs expressing only HIF-2α (23). ccRCC cell lines frequently express only HIF-2α and do not 
express functional HIF-1α due to biallelic alterations of the HIF1A locus (24). Knockdown of 
HIF1A in ccRCC cell lines that express both HIF-1α and HIF-2α promotes xenograft tumor 
formation (24). These studies argue that whereas HIF-2α activity is tumor promoting, there is a 
selection against HIF-1α expression or activity during the progression of some cases of ccRCC. On 
the other hand, the observations that HIF-1α is strongly expressed in single and multicellular 
clusters of VHL null cells and in cystic lesions in VHL patients (4), transgenic overexpression of 
Hif-1α in mouse proximal tubular epithelial cells causes a clear cell appearance, increased 
proliferation and a disorganized tubular morphology (25) and many human ccRCCs express HIF-1α 
and HIF-1α target genes (26), it may also be argued that HIF-1α plays an important role in 
promoting ccRCC development. These studies have largely focused on fully transformed, 
genetically complex ccRCC cell lines derived from advanced tumors and it remains unclear if and 
how HIF-1α and HIF-2α contribute to the earliest stages of initiation of ccRCC. 
 
An early event following VHL mutation is likely to be a profound alteration of cellular metabolic 
pathways. Numerous HIF-1α and/or HIF-2α-dependent metabolic changes occur in ccRCC cell 
lines, including elevated glucose uptake and conversion to lactate with a concomitant reduction in 
mitochondrial oxidation of pyruvate, reduced mitochondrial biogenesis, reduced mitochondrial 
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complex I activity, altered cytochrome c oxidase activity, increased pentose phosphate pathway 
flux, decreased oxidative glutaminolysis and increased lipogenesis through reductive glutamine 
metabolism (27-38). Since ccRCC cell lines have complex genetic backgrounds that arose during 
tumor evolution, it is possible that some of these metabolic changes might be driven by late-
occurring mutations that further modify metabolic pathways and allow ccRCC cells to proliferate 
efficiently in the metabolic environment imposed by constitutive HIF-α activity. For example, 
ccRCCs can harbor activating mutations in the PI3K-mTORC1 pathway, inactivating TP53 
mutations or can exhibit high levels of MYC expression or decreased FBP expression (1,38,39), all 
of which are known to influence numerous cellular metabolic pathways. The metabolic alterations 
that follow VHL mutation in otherwise genetically normal renal epithelial cells at the start of the 
process of tumor formation remain unclear. 
 
Given the importance of HIF-1α and HIF-2α in ccRCC, we asked whether the loss or constitutive 
activation of HIF-1α or HIF-2α alters renal epithelial proliferative homeostasis, metabolism and the 
initiation of renal cysts and tumours by undertaking a systematic approach of genetic deletion of 
Hif1a or Hif2a alone, together with Vhl and together with Vhl/Trp53 in renal epithelial cells in 
mice. 
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MATERIALS AND METHODS 
Mouse strains 
Hif1afl/fl (40) and Hif2afl/fl (41) mice were crossed with Ksp1.3-Cre;Vhlfl/fl (6), Ksp1.3-
Cre;Vhlfl/fl;Trp53fl/fl (8) or Ksp1.3-Cre/+ (42) mice. Littermate mice that lacked the Cre transgene 
served as wild type controls. 
 
Immunohistochemistry 
Immunohistochemistry and immunofluorescence of formalin fixed paraffin embedded tissues was 
performed as previously described (6,8) using antibodies listed in Supplementary Materials and 
Methods. 
 
Respirometry 
Biopsies (1 mm3) of renal cortex and medulla were assayed for oxygen consumption following the 
addition of different respiratory substrates and inhibitors using high-resolution respirometry 
(Oxygraph-2k, ORBOROS INSTRUMENTS Corp, Innsbruck, Austria) according to the protocol 
described in Supplementary Materials and Methods. 
 
Microarrays 
Primary adult mouse renal epithelial cells were cultured for 3 days and infected with Adeno-GFP 
(Vector Biolabs, 1060) or Adeno-Cre (Vector Biolabs, 1700) as described (8). mRNA was isolated 
4 days after adenovirus infection and Cy3- and Cy5-labelled cDNA from GFP- and Cre-samples 
was competitively hybridised to Mouse GE 4x44K v2 Microarrays (Agilent). Dye swap 
experiments were used to control potential dye-specific hybridisation effects. Analysis using 
R/Bioconductor package limma was based on the average fold expression level changes (Cre/GFP) 
of three independent biological experiments. MIAME compliant microarray data are accessible 
through GEO number GSE75745. 
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Histological stains 
H&E and PAS stains were conducted using standard protocols. For the visualization of lipids, 
frozen kidney sections were fixed with 10% formalin for 15 min, washed in tap water, equilibrated 
in 60% isopropanol and stained with Oil red O (3 mg/ml in 60% isopropanol) overnight at 4 °C. 
After rinsing in 60% isopropanol, sections were washed with water, counterstained with 
hematoxylin and mounted in Mowiol. 
 
Real time PCR 
RNA isolation, cDNA preparation and real time PCR were performed as described (6) using 
primers listed in Supplemental Materials and Methods. 
 
Mouse embryo fibroblasts (MEFs) 
MEFs were isolated from E13.5 embryos of relevant non-Cre expressing floxed mouse strains or 
C57BL/6 embryos (for wild type MEFs) and cultured as previously described (8) at 5% O2 and 5% 
CO2. MEFs were infected with adenovirus expressing Cre recombinase and GFP (Ad-Cre-GFP, 
Vector Biolabs, #1700) or GFP only (Ad-CMV-GFP, Vector Biolabs #1060). Detailed protocols for 
measuring ATP, ECAR, OCR, lactate production, glucose utilization and mitochondrial content are 
described in Supplementary Materials and Methods. 
 
Statistical analyses 
Unless otherwise stated, data are presented as mean ±	 std. dev. and statistical differences assessed 
using Student’s unpaired t-test. *, **, and *** denote p < 0.05, p < 0.01 and p < 0.001 respectively.   
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RESULTS 
Vhl deletion together with deletion of Hif1a or Hif2a does not cause renal tumors 
Most cases of ccRCC appear to arise from the proximal tubule although there is also evidence that 
some cases can arise from cells in other nephron segments (5). We employed the Ksp1.3-Cre 
transgene that induces epithelial cell-specific gene deletion widely throughout different segments of 
the nephron, including in a significant number of proximal tubular cells, as well as in epithelia of 
several genital tract tissues (42). We generated Ksp1.3-Cre;Vhlfl/fl  (VhlΔ/Δ) (6), Ksp1.3-Cre;Hif1afl/fl 
(Hif1aΔ/Δ), Ksp1.3-Cre;Hif2afl/fl (Hif2aΔ/Δ), Ksp1.3-Cre;Vhlfl/fl;Hif1afl/fl (VhlΔ/ΔHif1aΔ/Δ) and 
Ksp1.3-Cre;Vhlfl/fl;Hif2afl/fl (VhlΔ/ΔHif2aΔ/Δ) mice to achieve renal epithelial-specific loss or 
constitutive stabilization of HIF-1α and/or HIF-2α (Fig. 1A and B). Immunohistochemical staining 
confirmed the expected stabilization of either or both HIF-1α and HIF-2α in the relevant Vhl 
mutant genotypes (Fig. 1C and D). All of the above-described mutant mice were analysed at 6, 12 
and 18 months of age. Neither Hif1a nor Hif2a deletion alone had any effect on the morphology of 
kidneys. Vhl/Hif1a double deletion, but not Vhl/Hif2a double deletion, fully rescued (data not 
shown) the previously-reported hydronephrosis phenotype caused by Vhl deletion (6). This 
phenotypic rescue will be described in detail elsewhere. VhlΔ/Δ mice do not develop ccRCC 
precursor lesions or tumors (6). We reasoned that HIF-1α might act as an anti-proliferative factor 
that prevents tumor development following Vhl mutation. However, none of the genotypes 
exhibited cysts, dysplastic lesions or tumors in the cortex, medulla or papilla even when aged for 18 
months. Tubular epithelial cells in VhlΔ/ΔHif2aΔ/Δ mice frequently displayed a highly unusual 
“optically-clear” nucleus, characterised by a thin ring of chromatin surrounding a non-stained 
region in the centre (Supplementary Fig. S1). Papillary thyroid carcinomas display optically clear 
nuclei but this histological feature does not arise in ccRCCs. We conclude that the combination of 
loss of the many putative tumor suppressor functions of pVHL plus constitutive expression of the 
putative oncoprotein HIF-2α plus the absence of the putative tumor suppressor activity of HIF-1α 
does not cause cyst or tumor initiation. 
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Hif1a and Hif2a are both necessary for renal cyst and tumor formation caused by Vhl/Trp53 
deletion  
We next investigated potential requirements for Hif1a or Hif2a in the initiation of renal cysts and 
tumors in the Vhl/Trp53 double mutant background (8). We generated Ksp1.3-
Cre;Vhlfl/fl;Trp53fl/fl;Hif1afl/fl (VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ) and Ksp1.3-Cre;Vhlfl/fl;Trp53fl/fl;Hif2afl/fl 
(VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ) mice (Fig. 2A,B) and confirmed HIF-1α and HIF-2α stabilization in the 
relevant genotypes (Fig. 2C and D). PCRs specific for the recombined Vhl and Trp53 alleles 
demonstrated that these genes were deleted efficiently in these mice (Supplementary Fig. S2). We 
analyzed cohorts at 6 and 12 months of age. Table 1 shows a summary of the incidence of different 
phenotypes in each genotype and Fig. 2 shows examples of these phenotypes. We previously 
demonstrated (8) that VhlΔ/ΔTrp53Δ/Δ mice display hydronephrosis, seminal vesicle developmental 
abnormalities (Fig. 2F), sub-fertility and sub-viability and by 12 months of age these mice develop 
simple and atypical kidney cysts (Fig. 2B), kidney tumors (Fig. 2F), disorganized and multilayered 
epididymal epithelial cell growth (Fig. 2G), epididymal squamous metaplasia (Fig. 2H) and benign 
epididymal tumors at high penetrance. About one third of these mice also develop a variety of 
genital-urinary tract carcinomas (8). All of these phenotypes were completely absent in 
VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ mice. Six month-old VhlΔ/ΔTrp53Δ/Δ mice frequently displayed 
disorganized renal tubular epithelia with a clear cell appearance but this phenotype was not present 
in VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ mice (Fig. 2A). These mice developed only a few micro-cysts at a 
frequency that was not higher than littermate control mice (data not shown) and importantly no 
large renal cysts or tumors arose in mice aged 12 months (Fig. 2B, Table 1). Epididymides of 
VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ mice displayed nuclear atypia and mild epithelial disorganization (Fig. 2G 
and H), similar to the phenotypes observed in younger VhlΔ/ΔTrp53Δ/Δ mice (8) but did not develop 
epithelial dysplasia or squamous metaplasia. No malignant tumors were observed in any other 
genital-urinary tract organs in these mice (Table 1). Thus, HIF-1α activity is indispensible for the 
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initiation of kidney cyst and tumor formation and for the formation of genital-urinary tract 
malignancies.  
 
In contrast, VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ mice displayed several identical phenotypes to VhlΔ/ΔTrp53Δ/Δ 
mice, including hydronephrosis (data not shown), seminal vesicle developmental abnormalities 
(Fig. 2F), disorganized epididymal epithelial growth (Fig. 2G) and epididymal squamous 
metaplasia (Fig. 2H), although these epididymal phenotypes were present in only half of the mice 
(Table 1) and were much smaller lesions than those seen in VhlΔ/ΔTrp53Δ/Δ mice. Similarly to 
VhlΔ/ΔTrp53Δ/Δ mice, VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ mice were also sub-fertile and sub-viable, with many 
mice dying at various ages, possibly due to kidney failure caused by excessive hydronephrosis. 
While 6 month-old VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ mice displayed disorganized renal tubular epithelia with 
optically-clear nuclei (Fig. 2A), no large renal cysts or tumors (Fig.  2B), nor genital-urinary tract 
carcinomas were observed in 12 month-old mice. Thus, many of the pre-neoplastic and all of the 
neoplastic phenotypes resulting from combined deletion of Vhl and Trp53 are also dependent on 
HIF-2α activity.  
 
HIF-1α  and HIF-2α  both contribute to increased cellular proliferation in Vhl and Vhl/Trp53 
mutant mice 
Since HIF-1α and HIF-2α have been implicated in regulating the proliferation of ccRCC cells, we 
analysed the roles of HIF-1α and HIF-2α in proliferative control in mouse renal epithelia. Ki67 
staining to label proliferating epithelial cells in the renal cortex revealed that tubules in 6 month-old 
Vhl knockout mice displayed an increased number of proliferating cells. This phenotype was 
completely rescued by co-deletion of Hif1a and partially rescued by co-deletion of Hif2a (Fig. 3A 
and C), indicating a major and minor role of HIF-1α and HIF-2α, respectively, in causing increased 
cellular proliferation. We next asked whether the rescue of cyst and tumour formation in the 
Vhl/Trp53 mutant background was due to a requirement for HIF-1α or HIF-2α in causing enhanced 
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proliferation. In fact, Ki67 labelling revealed elevated numbers of proliferating epithelial cells in the 
renal cortices of 12 month-old VhlΔ/ΔTrp53Δ/Δ, VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ and 
VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ mice in comparison to littermate control mice (Fig. 3B and D) indicating 
that increased cellular proliferation is not the sole cause of cyst and tumor formation. Inter-genotype 
comparisons revealed that deletion of either Hif1a or Hif2a lowered proliferation in the Vhl/Trp53 
mutant background with loss of Hif1a causing a stronger decrease in proliferation than loss of 
Hif2a. The absence of a complete rescue by Hif1a deletion in the Vhl/Trp53 mutant background, in 
comparison to the complete rescue in the Vhl mutant background, argues that loss of Trp53 also 
contributes to increased proliferation in the Vhl/Trp53 mutant background. 
 
HIF-1α  regulates glycolysis, oxidative metabolism and mitochondrial abundance in renal 
epithelial cells 
To gain further molecular insights into HIF-1α- and HIF-2α-dependent processes in Vhl null cells 
that might be necessary for tumor initiation, we developed a system to culture primary renal 
epithelial cells derived from kidneys of adult Vhlfl/fl, Vhlfl/flHif1afl/fl, Vhlfl/flHif2afl/fl and 
Vhlfl/flHif1afl/flHif2afl/fl mice. Epithelial morphology (Supplementary Fig. S3A), Cdh1 mRNA 
expression (Supplementary Fig. S3B) and E-Cadherin protein expression (Supplementary Fig. S3C) 
were maintained for at least 12 days of culture, implying that the epithelial phenotype of these cells 
is largely preserved in this culture system. Cultures were infected with adenovirus expressing GFP 
as control or with adenovirus expressing Cre (Fig. 4A) and real time PCR confirmed the deletion of 
the floxed genes (Supplementary Fig. S3D). Microarray comparisons of global mRNA expression 4 
days after viral infection revealed a transcriptional signature induced by loss of Vhl that included 
753 probes that were significantly (p < 0.05) upregulated more than 1.5 fold and 451 probes 
downregulated more than 1.5 fold. This transcriptional signature was used to probe mRNA 
expression data derived from human normal kidney and ccRCC samples (GSE17895). 
Unsupervised clustering using the Vhl-deletion gene signature accurately segregated human 
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ccRCCs from normal kidney tissue (Supplementary Fig. S4), demonstrating that our culture system 
can identify ccRCC-relevant gene expression changes. We identified genes that were upregulated 
by loss of Vhl and that were dependent solely on Hif1a or solely on Hif2a or that remained 
upregulated when either Hif1a or Hif2a were deleted but not when both were deleted, indicating 
that they are targets of both HIF-1α and HIF-2α (Fig. 4B, Supplementary Table S1). While the 
Hif2a-dependent and Hif1a/Hif2a-dependent gene sets were not strongly enriched for sets of genes 
that participate in particular biological processes, the Hif1a-dependent target genes (Fig. 4C) 
encompassed numerous previously-identified hypoxia and HIF-α-targets (Bnip3, Bnip3l, Egln3, 
Loxl2, Ak4, Car9, Vegfa, P4ha2, Mif), including genes that regulate cellular metabolism 
(Supplementary Fig. S5) by promoting glycolytic flux (Slc2a1, Gpi1, Pfkl, Pfkfb3, Aldoa, Aldoc, 
Tpi1, Gapdh, Pgk1, Pgam1, Eno1), promoting glycogenolysis (Pygl, Pgm2), diverting glucose-
derived carbon from mitochondrial oxidation to lactate production and excretion (Pdk1, Ldha, 
Slc16a3) or regulating mitochondrial electron transport by inhibiting complex I (Ndufa4l2) (36). 
Real time PCR analyses of mRNA isolated from VhlΔ/Δ, VhlΔ/ΔHif1aΔ/Δ and VhlΔ/ΔHif2aΔ/Δ	  kidneys 
confirmed that several of these gene expression changes (Pgk1, Pdk1, Pfkfb3, Ldha, Ndufa4l2), as 
well as upregulation of Cox4-2, which alters the efficiency of cytochrome c oxidase (37), also occur 
upon Vhl deletion in vivo and demonstrated that, with the exception of Ndufa4l2, all were strictly 
dependent on Hif1a and independent of Hif2a (Fig. 4D). A similar Hif1a-dependent, Hif2a-
independent metabolic gene expression signature was observed in cultured primary renal epithelial 
cells (Supplementary Fig. S6A,B) and kidneys (Supplementary Fig. S6C) in the Vhl/Trp53 double 
mutant background, indicating that the induction of expression of these genes is independent of p53 
function. Moreover, elevated GLUT1 protein expression was detected in renal tubules in VhlΔ/Δ, 
VhlΔ/ΔTrp53Δ/Δ, VhlΔ/ΔHif2aΔ/Δ	   and	   VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ mice but not in VhlΔ/ΔHif1aΔ/Δ or 
VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ mice (Figs. 1E and 2E). 
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Since this Hif1a-activated transcriptional signature predicted decreased flux of pyruvate into 
mitochondria and decreased mitochondrial electron transport (Supplementary Fig. S5), we 
developed a method to analyse mitochondrial respiration in biopsies of the renal cortex and 
medulla. Oxygen consumption resulting from various steps of mitochondrial oxidation was assessed 
by sequential addition of the following metabolic intermediates or inhibitors; i) malate, octanoyl-
carnitine and ADP to determine medium chain fatty acid oxidation, ii) pyruvate and glutamate to 
determine complex I-specific activity, iii) succinate to determine total ATP synthase capacity, iv) 
rotenone to inhibit complex I and determine complex II-specific activity, v) antimycin A to block 
complex III, allowing the correction of residual O2 consumption and vi) TMPD and ascorbate to 
determine maximal cytochrome c oxidase activity (complex IV). Vhl deletion caused a decrease in 
all of the assays of respiratory capacity in the medulla but not cortex of these mice (Fig. 4E), 
consistent with the fact that the majority of tubules in the medulla are null for Vhl and the fact that 
proximal tubular cells, where gene deletion occurs in a minority of cells, are the most abundant cell 
type in the cortex. These effects were completely rescued in VhlΔ/ΔHif1aΔ/Δ but not VhlΔ/ΔHif2aΔ/Δ	  
kidneys (Fig. 4E), consistent with the Hif1a-dependency of the gene expression changes. Since 
HIF-1α has been shown to decrease mitochondrial abundance via multiple mechanisms (32,43), we 
analysed mitochondrial abundance in AQP2 expressing collecting duct principal cells using 
immunofluorescence for the mitochondrial outer membrane protein TOM20. Reduced TOM20 
staining intensity was observed in these cells in VhlΔ/Δ and in VhlΔ/ΔHif2aΔ/Δ	   kidneys, whereas 
VhlΔ/ΔHif1aΔ/Δ kidneys exhibited increased TOM20 staining (Fig. 5A-H and U), consistent with the 
measures of cellular respiration. Similar results were obtained in the Vhl/Trp53 mutant background 
(Supplementary Fig. S7E-M). We conclude that HIF-1α but not HIF-2α stabilization decreases 
mitochondrial abundance and oxidative capacity independently of p53 function in Vhl mutant renal 
tubular cells in vivo. 
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We next investigated whether the characteristic clear cell phenotype of ccRCC, believed to be 
caused by the cytoplasmic accumulation of lipids and glycogen, was also dependent on Hif1a. 
Indeed, tubular epithelial cells in VhlΔ/Δ, VhlΔ/ΔTrp53Δ/Δ, VhlΔ/ΔHif2aΔ/Δ and 
VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ	   mice, but not in VhlΔ/ΔHif1aΔ/Δ and VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ	   mice 
frequently demonstrated clear cell morphology (Fig. 5I-L and 2A-D). Tubules in Hif1aΔ/Δ and 
Hif2aΔ/Δ mice did not display morphological alterations (Supplementary Fig. S1). Tubules in 
VhlΔ/Δ, VhlΔ/ΔTrp53Δ/Δ, VhlΔ/ΔHif1aΔ/Δ, VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ, VhlΔ/ΔHif2aΔ/Δ and 
VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ kidneys all displayed strong accumulation of cytoplasmic glycogen 
droplets as assessed by periodic acid-Schiff (PAS) staining (Fig. 5M-P, Supplementary Fig. S7A-D) 
and the optically-clear nuclei in VhlΔ/ΔHif2aΔ/Δ and VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ mice also displayed 
strong glycogen accumulation (Fig. 5P, Supplementary Fig. S7D), which may be the cause of this 
phenotype. While several genes encoding enzymes of glycogenolysis and glycogen synthesis were 
upregulated in Vhl deficient kidneys, these gene expression changes were abolished by co-deletion 
of either Hif1a or Hif2a (Fig. 5W), suggesting that this is not the cause of glycogen accumulation. 
Surprisingly, no accumulation of lipids was observed in tubular cells in any genotype, as assessed 
by Oil red O (Fig. 5Q-T) and Nile red (data not shown) stainings. Peri-renal fat in the same samples 
served as positive control for these stainings (Fig. 5V).  Thus, while HIF-1α-dependent reductions 
in mitochondrial abundance and oxidative capacity correlate with the presence of a clear cell 
cytoplasm, neither glycogen nor lipid accumulation appear to be the cause of this phenotype.  
 
HIF-1α  induces reduced cellular ATP levels in Vhl deficient cells independently of p53 
We next turned to a primary cell culture-based system to gain more insight at the cellular level into 
the metabolic alterations that follow Vhl deletion. Since primary renal tubular epithelial cells 
rapidly de-differentiate after trypsinisation they were not suitable for these experiments. We instead 
utilized primary mouse embryo fibroblasts (MEFs) as a genetically tractable cell culture system and 
focused on alterations in glucose metabolism and oxygen consumption. We derived MEFs from 
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Vhlfl/fl, Vhlfl/flHif1afl/fl, Vhlfl/flHif2afl/fl and Vhlfl/flHif1afl/flHif2afl/fl embryos and infected them with 
adenoviruses expressing GFP (Adeno-GFP) or Cre (Adeno-Cre). The efficient deletion of all genes 
in the relevant floxed genotypes was confirmed by real time PCR (Supplementary Fig. S8). We 
investigated the dependence on Hif1a and Hif2a of the expression of a series of the key HIF-1α-
dependent metabolic genes that we identified in renal epithelial cells. The mRNA levels of Slc2a1, 
Pfkfb3, Pgk1, Ldha, Pdk1, NduFa4l2 and Cox 4-2 were elevated in Vhl mutant cells in a Hif1a-
dependent but Hif2a-independent manner (Fig. 6A), identically to the results seen in primary renal 
epithelial cells and in knockout kidneys. Deletion of Vhl induces premature senescence that can be 
rescued by co-deletion of Trp53 (8). Vhl/Trp53 double null MEFs also exhibited higher mRNA 
abundance of these genes (Fig. 6A), indicating that the gene expression pattern is not a secondary 
consequence of senescence, nor is it dependent on p53. Since this gene expression pattern is 
expected to promote the conversion of glucose-derived pyruvate into lactate at the expense of entry 
of pyruvate into the mitochondria for oxidative phosphorylation, we analysed cellular readouts of 
glycolytic flux in cells cultured at 20% O2. Modest increases in glucose utilization (Fig. 6B) and 
extracellular acidification rate (Fig. 6C), as well as increases in the amount of lactate secreted by 
the cells (Fig. 6D), were observed in Vhl and Vhl/Trp53 null MEFs. In contrast to these relatively 
small increases, there was a large decrease in oxygen consumption (Fig. 6E) in Vhl and Vhl/Trp53 
null MEFs that was not attributable to reduced mitochondrial mass, as assessed by NAO staining 
(Fig 6F). These results show that Vhl deletion causes a modest increase in glucose uptake and 
conversion to lactate but a large decrease in the activity of the mitochondrial TCA cycle, reflected 
by a lowered oxygen consumption rate. The reduced levels of oxidative phosphorylation that are not 
compensated by a large elevation in glucose flux to lactate suggested that cells may not be able to 
produce normal levels of ATP. Indeed, Vhl and Vhl/Trp53 deletion caused a decrease in cellular 
ATP levels (Fig. 6G) that is dependent on Hif1a but independent of Hif2a (Fig. 6H), consistent with 
the transcriptional effects of these gene deletions on metabolic regulatory genes.  
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DISCUSSION 
The molecular and cellular causes of ccRCC are incompletely understood. Biallelic inactivation of 
VHL is an early event in most ccRCCs but deletion of Vhl in renal epithelial cells in mice does not 
cause tumor formation (5). Correlative and functional genetic studies of human ccRCC have 
demonstrated that HIF-1α stabilization exerts a tumor suppressor-like activity while HIF-2α 
behaves oncogenically in the context of tumor cell proliferation (5). Here we tested the hypothesis 
that abolishing HIF-1α stabilization might allow hyperproliferation of Vhl mutant kidney epithelial 
cells in vivo, potentially allowing cysts or ccRCC tumors to form. In fact, Hif1a co-deletion rescued 
the increased epithelial cell turnover caused by Vhl deletion and VhlΔ/ΔHif1aΔ/Δ mice developed no 
renal proliferative abnormalities. Similar mouse models in which Vhl and Hif1a were deleted in 
renal epithelial cells under the control of different nephron segment-specific Cre transgenes also did 
not lead to tumor formation (44,45). Our VhlΔ/ΔHif2aΔ/Δ mice similarly did not develop renal cysts 
or tumors. Thus, despite the numerous putative tumor suppressor functions of Vhl, its deletion 
together with constitutive stabilization of HIF-1α and HIF-2α alone or together are insufficient for 
renal tumor formation. Previous studies employing various strategies to achieve HIF-1α and/or 
HIF-2α activation in Vhl wild type renal epithelia also failed to induce tumor formation beyond the 
stage of simple cysts or small dysplastic lesions (25,46-48). Vhl/Trp53 deletion leads to the 
formation of simple and atypical renal cysts, renal tumors as well as carcinomas in other organs of 
the genital tract (8). We anticipated that the tumor phenotype in these mice might be enhanced by 
Hif1a co-deletion. In fact, all phenotypes in these mice were completely rescued. Similarly, co-
deletion of Hif2a in this genetic background also completely prevented the formation of renal cysts, 
renal tumors and malignancies of the genital-urinary tract. Insofar as the Vhl/Trp53 deletion model 
mimics the initial stages of evolution of ccRCCs, these findings demonstrate that HIF-1α and HIF-
2α stabilization both play essential oncogenic roles in cyst and tumor formation. It will be 
interesting in further mouse genetic studies to determine whether HIF-1α and HIF-2α are also both 
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necessary for the formation of tumors induced by other mutations that cooperate with Vhl, such as 
Bap1 (9).  
 
It seems likely that HIF-1α and HIF-2α might each alter multiple cellular processes that are 
separately or cooperatively necessary for cyst and tumor evolution. While our studies uncoupled 
increased epithelial turnover from cyst and tumor formation, we identified several metabolic 
alterations that precede tumor formation. In Vhl mutant renal epithelial cells, HIF-1α induces a 
transcriptional program that promotes the glycolytic conversion of glucose to lactate and decreases 
mitochondrial oxidation of glucose- and fatty acid-derived carbons. HIF-1α also decreased the 
abundance of mitochondria in collecting duct epithelial cells, consistent with previous findings in 
cultured human cells that HIF-1α decreases mitochondrial biogenesis via MXI1-MYC-PGC1β and 
increases mitophagy via BNIP3 (32,43). Our microarray observation that Bnip3 expression is 
upregulated in Vhl deficient renal epithelial cells (Fig. 4C) provides the basis for future studies to 
uncover how Vhl loss reduces mitochondrial abundance. In established ccRCC cell lines, increasing 
mitochondrial abundance by constitutive PGC-1α expression causes decreased xenograft tumor 
growth (49), consistent with our correlative data that VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ	  mice do not show 
decreases in mitochondrial abundance and activity and do not develop cysts or tumors. These 
findings argue that a reduction in mitochondrial abundance promotes tumorigenesis. On the other 
hand, we show in MEFs that HIF-1α induces Warburg-like metabolism associated with increased 
conversion of glucose to lactate, decreased mitochondrial oxygen consumption and a lowered 
cellular level of ATP, implying that reduced cellular ATP levels may be an early cellular 
consequence of VHL gene deletion. The role that this mode of metabolism might play in promoting 
or inhibiting ccRCC formation remains to be determined but it is noteworthy in human ccRCCs that 
high mRNA expression levels of several of the HIF-1α-dependent metabolic genes that we identify 
in this study (including PFKM, ALDOB, PGK1, PGM2, ENO1, LDHA, PDK1), as well as higher 
levels of phosphorylated AMPK, a predicted consequence of HIF-1α-mediated reduction in cellular 
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ATP levels, correlate with better patient outcome (39). This finding argues that the HIF-1α 
metabolic transcriptional signature acts to restrain aggressive tumor behavior. Thus, it appears that 
different metabolic activities of HIF-1α may contribute differently to different aspects of tumor 
formation and progression. Additionally, it appears likely that mutations or alterations in the 
expression of other metabolism-regulating genes, such as decreased expression of FBP (38), may 
act together with HIF-1α to further alter cellular metabolic pathways to achieve a balance of high 
rates of glycolytic and pentose phosphate pathway flux and sufficient oxidative phosphorylation to 
provide the necessary metabolic intermediates and ATP to fuel efficient biosynthesis, cellular 
proliferation and tumor growth. 
 
VHL mutant “normal” tubular cells in VHL patient kidneys exhibit clear cell morphology (4), 
highlighting that this phenotype precedes tumor formation. We demonstrate that HIF-1α 
stabilization but not HIF-2α stabilization induces the clear cell phenotype, consistent with previous 
observations based on overexpression of stabilized mutants of HIF-1α and HIF-2α (25,48). 
Somewhat surprisingly, while decreased mitochondrial activity and abundance correlated with the 
presence of clear cell cytoplasm, the accumulation of glycogen deposits did not and renal tubules 
did not accumulate lipids. These findings contradict the widely-held idea that the clear cell 
phenotype results from cytoplasmic lipid and glycogen accumulation. 
 
Our studies encourage a modification of the idea that HIF-2α is the ccRCC oncogene and that HIF-
1α restrains tumor progression. We argue that while activation of HIF-1α or HIF-2α alone or 
together are insufficient for tumor formation following biallelic inactivation of VHL, their activities 
are each indispensible for the formation of cysts and tumors that arise as a consequence of 
cooperating secondary mutations. The frequent selection in human ccRCC for functional losses of 
the HIF1A gene (24) or for other post-transcriptional alterations that impair HIF-1α stability and 
promote HIF-2α activity (50) raises the intriguing idea that HIF-1α may switch during tumor 
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evolution from being a factor that is initially necessary for tumor formation (oncogene) to one that 
later restrains tumor progression (tumor suppressor). Our findings also raise the idea that 
pharmacological inhibition of either HIF-1α or HIF-2α may be sufficient to prevent ccRCC 
formation in patients with inherited VHL mutations. 
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   VhlΔ/ΔTrp53Δ/Δ	   VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ	   VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ	  
Number of renal cysts 399 (n=30 kidneys) 15 (n=30 kidneys) 10 (n=22 kidneys) 
Number of renal tumors 16 (n=30 kidneys) 0 (n=30 kidneys) 0 (n=22 kidneys) 
Number of genital-urinary tract 
carcinomas 
6 (n=17 mice) 0 (n=15 mice) 0 (n=18 mice) 
Incidence of epididymal 
dysplasia/squamous metaplasia 
100% (n=9 mice) 0% (n=7 mice) 50% (n=8 mice) 
Incidence of seminal vesicle 
abnormality 
100% (n=9 mice) 0% (n=7 mice) 100% (n=8 mice) 
 
Table 1: Summary of phenotypes in VhlΔ/ΔTrp53Δ/Δ, VhlΔ/ΔTrp53Δ/ΔHif1aΔ/Δ and 
VhlΔ/ΔTrp53Δ/ΔHif2aΔ/Δ	  mice aged 11 to 13 months. Numbers of renal cysts and renal tumours are 
derived from analysis of midline longitudinal sections of n kidneys of each genotype. Numbers of 
genital-urinary tract carcinomas represent the cumulative number of tumors arising in the 
epididymis, seminal vesicle, uterus and urothelium of n mice of each genotype. The incidence of 
epididymal and seminal vesicle phenotypes represents the % of n mice of each genotype that 
display the listed phenotypes. 
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FIGURE LEGENDS 
 
Figure 1. Renal epithelial cell-specific deletion of Vhl, Hif1a, Hif2a, Vhl/Hif1a and Vhl/Hif2a.  
H&E stainings of renal cortex (A) and medulla (B) and immunohistochemical stainings for HIF-1α 
(C), HIF-2α (D) and GLUT1 (E) in the renal cortex.  
 
Figure 2. Deletion of Vhl/Trp53, Vhl/Trp53/Hif1a and Vhl/Trp53/Hif2a in renal epithelial cells.  
(A,B) H&E stainings of renal cortex from mice aged 6 months (A) and 12 months (B). Arrowheads 
highlight disorganized tubules with clear cell cytoplasm and arrows highlight optically-clear nuclei, 
Cy labels cysts and Neo labels a neoplasm. Immunohistochemical stainings for HIF-1α (C), HIF-2α 
(D) and GLUT1 (E) in the renal cortex. (F) H&E stainings of vesicular glands from mice aged 6 
months. (G,H) H&E stainings of epididymides from mice aged 12 months. 
 
Figure 3. Control of renal epithelial cell proliferation by HIF-1α  and HIF-2α . 
(A,B) Ki67 staining of renal cortices of 6 month-old (A) or 12 month-old (B) mice. (C,D) Ki67 
positive tubular epithelial cells per field (0.36 mm2) in 6 month-old (C) or 12 month-old (D) mice. 
Mean ±	 SEM from 5 separate regions in 3-5 kidneys of each genotype. 
 
Figure 4. HIF-1α  stabilization inhibits mitochondrial oxidation in Vhl-deficient cells 
(A) Workflow for microarray analysis of mRNA expression 4 days after deletion of Vhl alone or 
together with Hif1a and/or Hif2a in primary renal epithelial cells. (B) Gene expression clustering of 
differentially expressed genes between Adeno-Cre and Adeno-GFP-treated cells. Rows represent 
mean log2 ratios values of 3 independent samples of each genotype. HIF-1α-specific or HIF-2α-
specific target genes or genes that are regulated by both HIF-1α and HIF-2 α are indicated. (C) 
Heat map of gene expression of HIF-1α-specific genes. (D) mRNA abundance of the indicated 
genes in kidneys deficient for Vhl, Vhl/Hif1a and Vhl/Hif2a. Mean ±	 std. dev. (n = 6 mice of each 
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genotype) gene expression ratios between Ksp1.3-Cre and wild type (WT) mice, normalized to 
expression of Rps12. (E) Respirometry of biopsies from cortex and medulla of wild type (+/+, black 
bars) and knockout (Ksp1.3-Cre/+, white bars) genotypes (n = 6 mice per genotype)  in Vhlfl/fl (left 
column), Vhlfl/flHif1afl/fl (middle column) and Vhlfl/flHif2afl/fl (right column) kidneys. Graphs depict 
oxygen consumption attributable to total ATP synthase capacity, complex I, complex II, complex 
IV and medium chain fatty acid oxidation.  
 
Figure 5. Cellular metabolic phenotypes in Vhl, Vhl/Hif1a and Vhl/Hif2a deficient mice. 
(A-H) Immunofluorescence stainings for AQP2, TOM20 and DAPI. A-D shows overlaid channels, 
E-H shows TOM20 fluorescence only, arrowheads highlight examples of collecting duct principal 
cells. (I-L) H&E staining of renal cortex. Arrowheads highlight epithelial cells with clear cell 
cytoplasm and arrows highlight optically-clear nuclei. (M-P) Periodic acid-Schiff (PAS) staining of 
the renal cortex. Arrows highlight optically clear nuclei that display strong accumulation of 
glycogen. (Q-T) Oil red O staining in the renal cortex. (U) Average TOM20 intensity in AQP2 
positive cells. 43-64 tubules were analysed in 7-11 separate regions per genotype. (V) Oil red O 
staining of peri-renal fat. (W) mRNA abundance of the indicated genes in kidneys deficient for Vhl, 
Vhl/Hif1a and Vhl/Hif2a (n = 6 mice of each genotype) of the ratios of gene expression between 
Ksp1.3-Cre and wild type (WT) mice, normalized to expression of Rps12. 
 
Figure 6. Impact of Vhl, Hif1a, Hif2a and Trp53 mutations on glycolysis, oxygen consumption 
and ATP production. 
(A) mRNA abundance of the indicated genes between Adeno-Cre and Adeno-GFP treated MEFs 
(72 hours after infection), normalized to expression of Rps12 (n=3). (B) Relative glucose 
utilization, (C) extracellular acidification rate (ECAR), (D) relative lactate production, (E) oxygen 
consumption rate (OCR) of Adeno-GFP or Adeno-Cre treated cultures of MEFs 72 hours after 
infection. B and D show pooled data from 3 independent experiments each assayed in quadruplicate 
	   	   	   	   	   28 
and C and E depict single representative experiments of 3 independent experiments each involving 
5 replicate assays per genotype. (F) Flow cytometry using 10-N-Nonyl acridine orange (NAO) 
staining. Filled grey curves show Adeno-GFP infected cells, non-filled curves show Adeno-Cre 
infected cells (G,H) Relative cellular ATP levels of Adeno-GFP and Adeno-Cre treated cells of the 
indicated genotypes. n=11-30 independent experiments, each with 3-5 technical replicates.  
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